# A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3

> **NCT00002161** · NA · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 400 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Adefovir dipivoxil

## Key facts

- **NCT ID:** NCT00002161
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 400 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002161, "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*